Clinical Study on the 2C3L Strategy Based on Marshall Venous Chemoablation for the Treatment of Persistent Atrial Fibrillation Combined With Heart Failure
(1) To evaluate the efficacy and safety of 2C3L strategy combined with VOM anhydrous ethanol chemical ablation for persistent atrial fibrillation complicated with heart failure; (2) To evaluate the effectiveness of high-efficiency ablation of atrial fibrillation complicated with heart failure.
• age:18y-80y
• First ablation on non valvular atrial fibrillation
• Persistent atrial fibrillation with LVEF≤40%
• The patient has symptoms related to atrial fibrillation, including but not limited to palpitations, premonitory syncope, syncope, fatigue, and shortness of breath, and is evaluated for clinical cardiac function between NYHA II-IV levels
• No response to antiarrhythmic drugs, unacceptable side effects, or unwillingness to take antiarrhythmic drugs.